Increased MMP-21 expression is associated with poor overall survival of patients with gastric cancer

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Wu, Tao ^a   Li, Yi ^a   Lu, Jianguo ^a   Qiao, Qing ^a   Bao, Guoqiang ^a   Wang, Nan ^a   He, Xianli ^a   Du, Xilin ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Gastric cancer; Matrix metalloproteinase 21; Prognosis

Indexed keywords

MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 21; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR INVASION;

ADENOCARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MATRIX METALLOPROTEINASES, SECRETED; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84871601619     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0323-8     Document Type: Article

References (34)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012;62:10-29.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
3. Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol. 2006;12:17-20.
4. Parsons SL, Watson SA, Brown PD, et al. Matrix metalloproteinases. Br J Surg. 1997;84:160-6.
5. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. 2000;36:1621-30.
6. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999;30(274):21491-4.
7. Nelson AR, Fingleton B, Rothenberg ML, et al. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000;18:1135-49.
8. Park HI, Ni J, Gerkema FE, et al. Identification and characterization of human endometase (matrix metalloproteinase-26) from endometrial tumor. J Biol Chem. 2000;275:20540-4.
9. Stetler-Stevenson WG. The role of matrix metalloproteinases in tumor invasion, metastasis and angiogenesis. Surg Oncol Clin N Am. 2001;10:383-92.
10. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001;93:178-93.
11. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 1999;189:300-8.
12. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997;89:1260-70.
13. Reis ST, Leite KR, Piovesan LF, et al. Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of bladder cancer. BMC Urol. 2012;12:18.
14. Song N, Sung H, Choi JY, et al. Preoperative serum levels of matrix metalloproteinase-2 (MMP-2) and survival of breast cancer among Korean women. Cancer Epidemiol Biomarkers Prev. 2012 Jun 5.
15. Ng KT, Qi X, Kong KL, et al. Overexpression of matrix metalloproteinase-12 (MMP-12) correlates with poor prognosis of hepatocellular carcinoma. Eur J Cancer. 2011;47:2299-305.
16. Chen R, Cui J, Xu C, et al. The Significance of MMP-9 Over MMP-2 in HCC invasiveness and recurrence of hepatocellular carcinoma after curative resection. Ann Surg Oncol. 2011 Jun 17.
17. Barresi V, Vitarelli E, Tuccari G, et al. MMP-9 expression in meningiomas: a prognostic marker for recurrence risk? J Neurooncol. 2011;102:189-96.
18. Chen T, Zhu J. Evaluation of EMMPRIN and MMP-2 in the prognosis of primary cutaneous malignant melanoma. Med Oncol. 2010;27:1185-91.
19. Zeng ZS, Huang Y, Cohen AM, et al. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol. 1996;14:3133-40.
20. Fujimoto D, Hirono Y, Goi T, et al. Prognostic value of protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1) in gastric cancer. Anticancer Res. 2008;28:847-54.
21. Partyka R, Gonciarz M, Jałowiecki P, et al. VEGF and metalloproteinase 2 (MMP-2) expression in gastric cancer tissue. Med Sci Monit. 2012; 18: BR130-4.
22. Noh S, Jung JJ, Jung M, et al. MMP-2 as a putative biomarker for carcinomatosis in gastric cancer. Hepatogastroenterology. 2011;58:2015-9.
23. Koskensalo S, Mrena J, Wiksten JP, et al. MMP-7 overexpression is an independent prognostic marker in gastric cancer. Tumour Biol. 2010;31:149-55.
24. Al-Batran SE, Pauligk C, Wirtz R, et al. The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer. Ann Oncol. 2011 Nov 23.
25. Yan D, Dai H, Liu JW. Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma. BMC Cancer. 2011;11:151.
26. Suomela S, Koljonen V, Skoog T, et al. Expression of MMP-10, MMP-21, MMP-26, and MMP-28 in merkel cell carcinoma. Virchows Arch. 2009;455:495-503.
27. Boyd S, Virolainen S, Pärssinen J, et al. MMP-10 (Stromelysin-2) and MMP-21 in human and murine squamous cell cancer. Exp Dermatol. 2009;18:1044-52.
28. Germani RM, Civantos FJ, Elgart G, et al. Molecular markers of micrometastasis in oral cavity carcinomas. Otolaryngol Head Neck Surg. 2009;141:52-8.
29. Qiu W, Zhou G, Zhai Y, et al. No association of MMP-7, MMP-8, and MMP-21 polymorphisms with the risk of hepatocellular carcinoma in a Chinese population. Cancer Epidemiol Biomarkers Prev. 2008;17:2514-8.
30. Bister V, Skoog T, Virolainen S, et al. Increased expression of matrix metalloproteinases-21 and -26 and TIMP-4 in pancreatic adenocarcinoma. Mod Pathol. 2007;20:1128-40.
31. Shagisultanova EI, Novikova IA, Sidorenko YS, et al. The matrix metalloproteinase-21 gene 572C/T polymorphism and the risk of breast cancer. Anticancer Res. 2004;24:199-201.
32. Ahokas K, Lohi J, Illman SA, et al. Matrix metalloproteinase-21 is expressed epithelially during development and in cancer and is up-regulated by transforming growth factor-beta1 in keratinocytes. Lab Invest. 2003;83:1887-99.
33. Wu T, Li Y, Liu X, et al. Identification of high-risk stage II and stage III colorectal cancer by analysis of MMP-21 expression. J Surg Oncol. 2011;104:787-91.
34. Rhodes A, Jasani B, Barnes DM, et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol. 2000;53:125-30.